- Home
- YHNA vs HLVX Comparison
YHNA vs HLVX Comparison
Compare YHNA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHNA
- HLVX
- Stock Information
- Founded
- YHNA 2023
- HLVX 2020
- Country
- YHNA Hong Kong
- HLVX United States
- Employees
- YHNA N/A
- HLVX N/A
- Industry
- YHNA
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- YHNA
- HLVX Health Care
- Exchange
- YHNA Nasdaq
- HLVX Nasdaq
- Market Cap
- YHNA 79.9M
- HLVX 93.1M
- IPO Year
- YHNA 2024
- HLVX 2022
- Fundamental
- Price
- YHNA $10.07
- HLVX $1.90
- Analyst Decision
- YHNA
- HLVX Hold
- Analyst Count
- YHNA 0
- HLVX 5
- Target Price
- YHNA N/A
- HLVX $2.33
- AVG Volume (30 Days)
- YHNA 21.1K
- HLVX 324.9K
- Earning Date
- YHNA 01-01-0001
- HLVX 11-07-2024
- Dividend Yield
- YHNA N/A
- HLVX N/A
- EPS Growth
- YHNA N/A
- HLVX N/A
- EPS
- YHNA N/A
- HLVX N/A
- Revenue
- YHNA N/A
- HLVX N/A
- Revenue This Year
- YHNA N/A
- HLVX N/A
- Revenue Next Year
- YHNA N/A
- HLVX N/A
- P/E Ratio
- YHNA N/A
- HLVX N/A
- Revenue Growth
- YHNA N/A
- HLVX N/A
- 52 Week Low
- YHNA $10.00
- HLVX $1.55
- 52 Week High
- YHNA $11.28
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- YHNA N/A
- HLVX 42.75
- Support Level
- YHNA N/A
- HLVX $1.87
- Resistance Level
- YHNA N/A
- HLVX $2.15
- Average True Range (ATR)
- YHNA 0.00
- HLVX 0.09
- MACD
- YHNA 0.00
- HLVX -0.02
- Stochastic Oscillator
- YHNA 0.00
- HLVX 21.87
About YHNA YHN Acquisition I Limited Ordinary Shares
YHN Acquisition I Ltd is a newly organized blank check company for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.